Clinical Trials Logo

Central Visual Impairment clinical trials

View clinical trials related to Central Visual Impairment.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05456581 Recruiting - Clinical trials for Macular Degeneration

Scotoma Perimetry Oculomotor Training

SPOT
Start date: November 1, 2022
Phase: N/A
Study type: Interventional

The proposed research is relevant to public health because a greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has potential to benefit millions of individuals suffering from low vision. The treatment of low vision is particularly relevant to the mission of the NEI to support research on visual disorders, mechanisms of visual function and preservation of sight. Declines in vision are particularly common in older adults and thus increasing our understanding of how to cre- ate effective means of improving vision is also highly relevant to the mission of the NIA to support research on aging and the health and well-being of older people.

NCT ID: NCT05454124 Recruiting - Clinical trials for Macular Degeneration

Factors in Learning And Plasticity: Macular Degeneration

FLAP
Start date: November 1, 2022
Phase: N/A
Study type: Interventional

A greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has the potential to benefit millions of individuals suffering from low vision. The treatment of low vision is particularly relevant to the mission of the NEI to support research on visual disorders, mechanisms of visual function, and preservation of sight. The comparison of different training and outcome factors is in line with the NIMH RDOC framework and studies in an aging population are consistent with the mission of the NIA.

NCT ID: NCT05439759 Recruiting - Clinical trials for Macular Degeneration

Factors in Learning And Plasticity: Healthy Vision

FLAP
Start date: October 24, 2022
Phase: N/A
Study type: Interventional

A greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has the potential to benefit millions of individuals suffering from low vision. The treatment of low vision is particularly relevant to the mission of the National Eye Institute (NEI) to support research on visual disorders, mechanisms of visual function, and preservation of sight. The comparison of different training and outcome factors is in line with the National Institute of Mental Health (NIMH) Research Domain Criteria (RDOC) framework and studies in an aging population are consistent with the mission of the National Institute on Aging (NIA).